Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROCRIT for Chemotherapy-Induced Peripheral Neuropathy
NCT00267007Phase 2Terminated
- Sponsor
- Johnson & Johnson
- Start
- Jun 2006
- Primary completion
- Aug 2008
- Modality
- Biologic, rProtein (Recombinant Protein)
- Countries
- 1
01
Overview
A Phase 2 trial of epoetin alfa in chemotherapy-induced peripheral neuropathy (CIPN), sponsored by Johnson & Johnson. Started Jun 2006; status: terminated.
02
Drugs
epoetin alfa
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT00267007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00267007.